Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings.

@article{Cressey2007IndinavirritonavirRA,
  title={Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings.},
  author={Tim Roy Cressey and Nottasorn Plipat and Federica Fregonese and Kulkanya Chokephaibulkit},
  journal={Expert opinion on drug metabolism & toxicology},
  year={2007},
  volume={3 3},
  pages={347-61}
}
For over a decade, indinavir has been approved for the treatment of HIV/AIDS; however, following the introduction of new protease inhibitors (PIs) with improved safety and pharmacologic profiles, its use in developed countries has become almost obsolete. In contrast, in resource-limited settings where the majority of people living with HIV/AIDS reside, indinavir is part of the most affordable PI-based highly active antiretroviral treatment regimen. A major drawback of indinavir use is renal… CONTINUE READING